Literature DB >> 17313612

Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.

C-S Li1, B-C Cheng, W Ge, J-F Gao.   

Abstract

The aim of this study was to evaluate the individual and combined diagnostic value of five tumour markers in the elderly patients with pleural effusions. Serum and pleural fluid levels of cytokeratin fragment 19 (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) were assayed in 32 elderly patients with malignant pleural effusions resulting from advanced lung cancer and in 30 elderly patients with benign pleural effusions by ELISA. Serum levels of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 in patients with malignant pleural effusions were 12.84 +/- 6.48 microg/l, 22.07 +/- 11.25 microg/l, 65.74 +/- 30.26 kU/l, 56.32 +/- 25.6 kU/l and 71.86 +/- 31.45 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01). Pleural fluid levels of CYFRA21-1, CA15-3, CA19-9 and CA125 except NSE in patients with malignant pleural effusions were 18.64 +/- 8.15 microg/l, 59.31 +/- 27.35 kU/l, 48.24 +/- 21.56 kU/l and 62.16 +/- 27.79 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01). The parallel combined testing of five tumour markers in serum increased the diagnostic sensitivity to 90.6%, and serial combined testing increased the diagnostic specificity to 93.3%. The sensitivity (%) and specificity (%) of these tumour markers in pleural fluid were as follows: CYFRA21-1, 84.4/90; CA15-3, 62.5/73.3; CA19-9, 37.5/66.7; CA125, 56.3/70; for differentiating malignant effusions from benign effusions. When CYFRA21-1 and CA15-3 combined, the sensitivity and specificity were increased (100% and 90% respectively). Serum and pleural fluid levels of the five tumour markers shows certain values in the diagnosis and differentiate diagnosis for malignant pleural effusions in the elderly patients from benign. The combined assay of five tumour markers in serum and the CYFRA21-1 combined with CA15-3 in pleural fluid were helpful and can increase the sensitivity and specificity in diagnosing malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313612     DOI: 10.1111/j.1742-1241.2006.01111.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  10 in total

1.  Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.

Authors:  P Korczynski; R Krenke; A Safianowska; K Gorska; M B Abou Chaz; M Maskey-Warzechowska; A Kondracka; J Nasilowski; R Chazan
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

2.  Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array.

Authors:  Till Braunschweig; Joon-Yong Chung; Chel Hun Choi; Hanbyoul Cho; Qing-Rong Chen; Ran Xie; Candice Perry; Javed Khan; Stephen M Hewitt
Journal:  Diagn Pathol       Date:  2015-05-29       Impact factor: 2.644

3.  Biomarkers for screening of lung cancer and pre-neoplastic lesions in a high risk Chilean population.

Authors:  Marta I Adonis; Jose Díaz; Veronica R Miranda; Marco Chahuan; Alcides Zambrano; Hugo C Benitez; Monica Campos; Pablo Avaria; Ulises Urzúa; Pedro Marín; Mariela Gohurdett; Yasna Cisterna; Lionel Gil
Journal:  Biol Res       Date:  2014-11-25       Impact factor: 5.612

4.  Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Qiang Wu; Min Li; Shu Zhang; Lu Chen; Xingting Gu; Feng Xu
Journal:  Exp Ther Med       Date:  2014-10-30       Impact factor: 2.447

5.  Neuron-specific enolase as a novel biomarker reflecting tuberculosis activity and treatment response.

Authors:  Sung-Jin Nam; Jee-Yeong Jeong; Tae-Won Jang; Mann-Hong Jung; Bong-Kwon Chun; Hee-Jae Cha; Chul-Ho Oak
Journal:  Korean J Intern Med       Date:  2016-06-03       Impact factor: 2.884

6.  [Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion].

Authors:  Hongmei Li; Junhua Fu; Yuande Xiu; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-06

7.  Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.

Authors:  Feng Yang-Chun; Feng Min; Zhang Di; Huang Yan-Chun
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

8.  Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis.

Authors:  Jing Zhu; Mei Feng; Liqun Liang; Ni Zeng; Chun Wan; Ting Yang; Yongchun Shen; Fuqiang Wen
Journal:  BMC Cancer       Date:  2017-08-30       Impact factor: 4.430

9.  Serum enolase-2, high-sensitivity C-reactive protein, and serum cholesterol in smear-positive drug-naïve pulmonary tuberculosis.

Authors:  Suhail Ahmed Almani; Tariq Zaffar Shaikh; Haji Khan Khoharo; Ikramuddin Ujjan
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

10.  Diagnostic value of tumour markers in pleural effusions.

Authors:  Darian Volarić; Veljko Flego; Gordana Žauhar; Ljiljana Bulat-Kardum
Journal:  Biochem Med (Zagreb)       Date:  2018-01-10       Impact factor: 2.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.